As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
Despite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy’s first steps into the market indicate there is still room to grow.
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door Read More »
